药学学报, 2018, 53(7): 1023-1029
引用本文:
王莎莎, 张钊, 张欣, 龙倩, 贺文彬, 陈乃宏. 中药免疫治疗阿尔茨海默病的研究进展[J]. 药学学报, 2018, 53(7): 1023-1029.
WANG Sha-sha, ZHANG Zhao, ZHANG Xin, LONG Qian, HE Wen-bin, CHEN Nai-hong. Advances in immunotherapy of Alzheimer's disease with traditional Chinese medicine[J]. Acta Pharmaceutica Sinica, 2018, 53(7): 1023-1029.

中药免疫治疗阿尔茨海默病的研究进展
王莎莎1, 张钊2, 张欣1, 龙倩1, 贺文彬1, 陈乃宏1,2
1. 山西中医药大学中药学院, 山西 太原 030619;
2. 中国医学科学院、北京协和医学院药物研究所, 北京 100050
摘要:
阿尔茨海默病(Alzheimer's disease,AD)是一种常见的神经退行性疾病,临床以进行性认知功能障碍为核心症状,目前尚无理想的治疗策略。随着免疫学在中枢神经系统研究的深入,在临床前研究、遗传学以及生物信息学等不同领域的研究均显示,免疫功能异常是导致AD发病的原因之一,涉及AD的起始、维持和恶化阶段。我国拥有丰富的天然药物资源和临床应用经验,发现了大量的既可调控免疫功能,又对AD症状有所改善的天然药物和有效部位,本文仅对近年来通过免疫调控改善AD症状的研究进行综述,为从天然药物中探寻新型抗AD药物提供新的思路和线索。
关键词:    阿尔茨海默病      免疫治疗      炎症反应      中药     
Advances in immunotherapy of Alzheimer's disease with traditional Chinese medicine
WANG Sha-sha1, ZHANG Zhao2, ZHANG Xin1, LONG Qian1, HE Wen-bin1, CHEN Nai-hong1,2
1. Shanxi University of Traditional Chinese Medicine, Taiyuan 030619, China;
2. Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
Abstract:
Alzheimer's disease (AD) is a type of common neurodegenerative disease. The main clinical symptom of the disease is progressive cognitive dysfunction, which has no effective therapy yet. With the in-depth immunology study in the central nervous system, studies in different fields such as preclinical phase, genetics and bioinformatics have shown that immune dysfunction contribute to the pathogenesis of AD, including the beginning, maintenance and deterioration stage in AD. China has a wealth of natural medicine resources and clinical experiences. A large number of natural drugs and effective components both can regulate the immune function and ameliorate the symptoms in AD. This review summarizes the researches of ameliorating the symptoms in AD through immunization regulation in recent years with an aim to provide new ideas and clues in the study of new anti-AD drugs using natural medicines.
Key words:    Alzheimer's disease    immunotherapy    inflammation    traditional Chinese medicine   
收稿日期: 2017-10-16
DOI: 10.16438/j.0513-4870.2017-1013
基金项目: 国家自然科学基金资助项目(81603316,81603315);中国医学科学院医学与健康科技创新工程经费资助(2016-I2M-1-004).
通讯作者: 陈乃宏,Tel:86-10-63165177,Fax:86-10-63165211,E-mail:chennh@imm.ac.cn
Email: chennh@imm.ac.cn
相关功能
PDF(240KB) Free
打印本文
0
作者相关文章
王莎莎  在本刊中的所有文章
张钊  在本刊中的所有文章
张欣  在本刊中的所有文章
龙倩  在本刊中的所有文章
贺文彬  在本刊中的所有文章
陈乃宏  在本刊中的所有文章

参考文献:
[1] Lee JH, Kahn A, Cheng R, et al. Disease-related mutations among Caribbean Hispanics with familial dementia[J]. Mol Genet Genomic Med, 2014, 2:430-437.
[2] Tanzi RE. Twenty years of the Alzheimer's disease amyloid hypothesis:a genetic perspective[J]. Cell, 2005, 120:545-555.
[3] Rossi G, Giaccone G, Maletta R, et al. A family with Alzheimer disease and strokes associated with A713T mutation of the APP gene[J]. Neurology, 2004, 63:910-912.
[4] Kvetnoĭ IM, Kvetnaia TV, Ⅱu R, et al. Expression of beta-amyloid and tau-protein in mastocytes in Alzheimer disease[J]. Arkh Patol, 2003, 65:36-39.
[5] Bloom GS. Amyloid-β and tau:the trigger and bullet in Alzheimer disease pathogenesis[J]. JAMA Neurol, 2014, 71:505-508.
[6] Joshi P, Benussi L, Furlan R, et al. Extracellular vesicles in Alzheimer's disease:friends or foes? Focus on Aβ-vesicle interaction[J]. Int J Mol Sci, 2015, 16:4800-4813.
[7] Dong XX, Wang Y, Qin ZH. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases[J]. Acta Pharmacol Sin, 2009, 30:379-387.
[8] Heppner FL, Ransohoff RM, Becher B. Immune attack:the role of inflammation in Alzheimer disease[J]. Nat Rev Neurosci, 2015, 16:358-372.
[9] Gyoneva S, Swanger SA, Zhang J, et al. Altered motility of plaque-associated microglia in a model of Alzheimer's disease[J]. Neuroscience, 2016, 330:410-420.
[10] Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer's disease[J]. N Engl J Med, 2013, 368:117-127.
[11] Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer's disease[J]. N Engl J Med, 2013, 368:107-116.
[12] Bradshaw EM, Chibnik LB, Keenan BT, et al. CD33 Alzheimer's disease locus:altered monocyte function and amyloid biology[J]. Nat Neurosci, 2013, 16:848-850.
[13] Wisniewski T, Goñi F. Immunotherapy for Alzheimer's disease[J]. Biochem Pharmacol, 2014, 88:499-507.
[14] Lv MN. Advance in immunotherapy for Alzheimer's disease[J]. J Chin Pract Diagn Ther (中华实用诊断与治疗杂志), 2014, 28:1047-1049.
[15] Peng Y, Li PP, Li L, et al. Progress of clinical trials in Alzheimer's disease drugs[J]. Acta Pharm Sin (药学学报), 2016, 51:1185-1195.
[16] Wang Y, Kan H, Yin Y, et al. Protective effects of ginsenoside Rg1 on chronic restraint stress induced learning and memory impairments in male mice[J]. Pharmacol Biochem Behav, 2014, 120:73-81.
[17] Zhu J, Mu X, Zeng J, et al. Ginsenoside Rg1 prevents cognitive impairment and hippocampus senescence in a rat model of D-galactose-induced aging[J]. PLoS One, 2014, 9:e101291.
[18] Hu Y, Li C, Shen W. Gastrodin alleviates memory deficits and reduces neuropathology in a mouse model of Alzheimer's disease[J]. Neuropathology, 2014, 34:370-377.
[19] Chen GH, Huang WF. Progress in pharmacological effects of compositions of Astragalus membranaceus[J]. Chin J New Drugs (中国新药杂志), 2008, 17:1482-1485.
[20] Tohda C, Tamura T, Matsuyama S, et al. Promotion of axonal maturation and prevention of memory loss in mice by extracts of Astragalus mongholicus[J]. Br J Pharmacol, 2006, 149:532-541.
[21] Zhang Q, Du XP, Xu YP, et al. The effects of Gouqi extracts on Morris maze learning in the APP/PS1 double transgenic mouse model of Alzheimer's disease[J]. Exp Ther Med, 2013, 5:1528-1530.
[22] Mao J, Huang S, Liu S, et al. A herbal medicine for Alzheimer's disease and its active constituents promote neural progenitor proliferation[J]. Aging Cell, 2015, 14:784-796.
[23] Zhang MX. The Studies on Anti-Alzheimer's Disease Fraction of Acorus tatarinowii and Its Preliminary Material Basis (石菖蒲抗老年痴呆活性部位的确定及其初步物质基础研究)[D]. Shanghai:China Stata Institute of Pharmaceutical Industry, 2016.
[24] Chang WG, Teng JF. β-Asarone prevents Aβ25-35-induced inflammatory responses and autophagy in SH-SY5Y cells:down expression Beclin-1, LC3B and up expression Bcl-2[J]. Int J Clin Exp Med, 2015, 8:20658-20663.
[25] Lim HW, Kumar H, Kim BW, et al. β-Asarone (cis-2,4,5-trimethoxy-1-allyl phenyl), attenuates pro-inflammatory mediators by inhibiting NF-κB signaling and the JNK pathway in LPS activated BV-2 microglia cells[J]. Food Chem Toxicol, 2014, 72:265-272.
[26] Chen C, Li X, Gao P, et al. Baicalin attenuates Alzheimer-like pathological changes and memory deficits induced by amyloid β1-42, protein[J]. Metab Brain Dis, 2015, 30:537-544.
[27] Xiong J, Wang C, Chen H, et al. Aβ-induced microglial cell activation is inhibited by baicalin through the JAK2/STAT3 signaling pathway[J]. Int J Neurosci, 2014, 124:609-620.
[28] Wang W, Zhou PH, Xu CG, et al. Baicalein attenuates renal fibrosis by inhibiting inflammation via down-regulating NF-κB and MAPK signal pathways[J]. J Mol Histol, 2015, 46:283-290.
[29] Wang ZY, Liu JG, Li H, et al. Pharmacological effects of active components of Chinese herbal medicine in the treatment of Alzheimer's disease:a review[J]. Am J Chin Med, 2016, 44:1525-1541.
[30] Shi X, Zheng Z, Li J, et al. Curcumin inhibits Aβ-induced microglial inflammatory responses in vitro:involvement of ERK1/2 and p38 signaling pathways[J]. Neurosci Lett, 2015, 594:105-110.
[31] Ihl R, Tribanek M, Bachinskaya N. Efficacy and tolerability of a once daily formulation of Ginkgo biloba extract EGb 761® in Alzheimer's disease and vascular dementia:results from a randomised controlled trial[J]. Pharmacopsychiatry, 2012, 45:41-46.
[32] Yang M, Xu DD, Zhang Y, et al. A systematic review on natural medicines for the prevention and treatment of Alzheimer's disease with meta-analyses of intervention effect of ginkgo[J]. Am J Chin Med, 2014, 42:505-521.
[33] Shi C, Liu J, Wu F, et al. Ginkgo biloba extract in Alzheimer's disease:from action mechanisms to medical practice[J]. Int J Mol Sci, 2010, 11:107-123.
[34] Liu X, Hao W, Qin Y, et al. Long-term treatment with Ginkgo biloba extract EGb 761 improves symptoms and pathology in a transgenic mouse model of Alzheimer's disease[J]. Brain Behav Immun, 2015, 46:121-131.
[35] Yuan S, Gao K, Wang D, et al. Evodiamine improves cognitive abilities in SAMP8 and APPswe/PS1E9 transgenic mouse models of Alzheimer's disease[J]. Acta Pharmacol Sin, 2011, 32:295-302.
[36] Wang Q, Xiao B, Cui S, et al. Triptolide treatment reduces Alzheimer's disease (AD)-like pathology through inhibition of BACE1 in a transgenic mouse model of AD[J]. Dis Model Mech, 2014, 7:1385-1395.
[37] Cai Q, Li Y, Pei G. Polysaccharides from Ganoderma lucidumattenuate microglia-mediated neuroinflammation and modulate microglial phagocytosis and behavioural response[J]. J Neuroinflamm, 2017, 14:63.
[38] Lu F, Li X, Li W, et al. Tetramethylpyrazine reverses intracerebroventricular streptozotocin-induced memory deficits by inhibiting GSK-3β[J]. Acta Biochim Biophy Sin, 2017, 49:722-728.
[39] Liu CA, Zhu J, Cai B, et al. Tetramethylpyrazine protect rats against the inflammation and Aβ(25-35) induced ROS by targeting the RAGE-ERK1/2-p38-NFκB pathway[J]. Chin Pharm J (中国药学杂志), 2014, 49:1126-1132.
相关文献:
1.庞晓丛, 王喆, 方坚松, 连雯雯, 赵嬴, 康德, 刘艾林, 杜冠华.治疗阿尔茨海默病的中药有效成分的网络药理学研究[J]. 药学学报, 2016,51(5): 725-731